Navigation Links
Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntington's Disease Model
Date:9/16/2008

Study Published in the Proceedings of the National Academy of Sciences

WALTHAM, Mass., Sept. 16 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported publication of a preclinical study demonstrating that a novel histone deacetylase (HDAC) inhibitor improved disease symptoms in a transgenic animal model of Huntington's disease. The study, led by scientists at The Scripps Research Institute, demonstrated that oral administration of the drug candidate to the mice after the onset of symptoms slowed the progression of disease. Treated animals showed superior motor performance by multiple measures, reduced loss of body weight, reduced brain atrophy and improved overall appearance compared to untreated animals. Huntington's mice were also analyzed for changes in the hundreds of genes whose expression in the brain is altered in the mouse model of Huntington's, as well as in humans with Huntington's disease. Using gene microarrays, the researchers identified genes in three brain regions whose expression was altered in the Huntington's mice and whose expression was altered by treatment with the HDAC inhibitor. Treatment partially normalized the expression level of approximately 90% of these genes with 32% being restored to normal levels. These results suggest that an HDAC inhibitor may be useful in treating Huntington's disease and that specific genes may be useful as biomarkers in clinical trials. The research was conducted using a compound that is covered by Repligen's exclusive license from The Scripps Research Institute. The study entitled "The HDAC Inhibitor 4b Ameliorates the Disease Phenotype and Transcriptional Abnormalities in Huntington's Disease Transgenic Mice" will be published the week of September 15, 200
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Missouri (PRWEB) December 23, 2014 GMO ... Swiss biotechnology company, Syngenta, are in the process of ... proceedings. The consolidated case is In Re: Syngenta AG ... U.S. District Court for the District of Kansas. , ... has been handed over to U.S. District Judge John ...
(Date:12/24/2014)... December 23, 2014 The ... such as its definition, classification, application and ... specification, manufacturing process, and product cost structure. ... applications. The analysis also covers upstream raw ... industry development trend and proposals. In the ...
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, ... focused on gynecologic disease, announced today that investors ... , Birchview Fund LLC and several Vermillion directors ... unregistered shares of Vermillion,s common stock and warrants ... in a private placement.  Under ...
(Date:12/22/2014)... The Center for Professional Innovation ... training across the life sciences industry, has partnered with ... to provide the organization's members with discounted classroom courses, ... the more than 350 sessions across 80 course titles. ... when registering for a public course at ...
Breaking Biology Technology:Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3
... Md., Oct. 12 Sequella, Inc., a clinical-stage ... treat life-threatening infectious diseases, today announced that it ... (SBIR) grant from the National Institutes of Health ... (NIAID) for the development of SQ641, Sequella,s lead ...
... Calif., Oct. 12 Raptor Pharmaceutical Corp. ("Raptor" or ... from the completed treatment phase of its open-label Phase ... in adolescent patients with non-alcoholic steatohepatitis ("NASH"), a progressive ... 5% of the U.S. population. At the completion of ...
... , ... singer, Cynthia Basinet petitions the United Nations Sixty-fourth General Assembly Fourth Committee on behalf ... ... and singer, Cynthia Basinet petitions the United Nations Sixty-fourth General Assembly Fourth Committee on ...
Cached Biology Technology:Sequella Obtains Funding to Continue Expansion of its Anti-infectives Pipeline 2Sequella Obtains Funding to Continue Expansion of its Anti-infectives Pipeline 3Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) 2Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) 3Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) 4Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) 5Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) 6Actress and Singer, Cynthia Basinet Petitions United Nations 2
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... entertainer and security consultant, Apollo Robbins for ... smart wallet.  Apollo Robbins ... 7 th , 2015, demonstrating some of his famous ...
(Date:12/19/2014)... 18, 2014  23andMe, Inc., the leading personal genetics ... pinpoints fine-scale differences in genetic ancestry of individuals from ... Since immigrants first arrived more than four hundred ... has served as a meeting place for peoples from ... the ongoing mixing of peoples with African, European, and ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 423andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... Vertebral fractures are a common cause of ... powerful predictors of future spine and hip fractures. ... simply fail to recognize vertebral fractures in their ... intervention is often not initiated. The Vertebral ...
... CHICAGO, IL (May 8, 2011) Research being ... individuals for hepatitis C based on age instead of ... well as prevent liver disease. Additionally, the rate of ... disease and type 2 diabetes is relatively low, and ...
... the Faculty of Medicine & Dentistry at the University ... kill neurons. This finding is significant because a specific ... medical community as a potential treatment for MS and ... post-doctoral fellow, Yohannes Haile, both from the Division of ...
Cached Biology News:New IOF teaching tool helps health professionals identify vertebral fractures 2Strides in identifying and improving screening practices and treatment for liver diseases 2Discovery demonstrates potential MS therapy could kill brain cells 2
Mouse monoclonal antibody raised against a partial recombinant ST3GAL2. NCBI Entrez Gene ID = ST3GAL2...
... Apoptosis is an evolutionarily conserved form of ... process. The central component of this ... called caspases. These enzymes participate in ... in response to pro-apoptotic signals and result ...
... DNA Visualizer Extraction Kit is manufactured for ... DNA damage byexposure to UV light. The ... is often used for DNA-cloning work. The ... bromide and exposure of UV light damages ...
...
Biology Products: